1. Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine
- Author
-
Viktoria Knöbl, Lukas Maier, Stefan Grasl, Carmen Kratzer, Felix Winkler, Vanessa Eder, Hubert Hayden, Maria Amparo Sahagun Cortez, Monika Sachet, Rudolf Oehler, Sophie Frantal, Christian Fesl, Karin Zehetner, Georg Pfeiler, Rupert Bartsch, Florian Fitzal, Christian F. Singer, Martin Filipits, Michael Gnant, and Christine Brostjan
- Subjects
Aromatase inhibitor ,Breast cancer ,Estrogen receptor ,Letrozole ,Monocyte ,Stimuvax ,Medicine - Abstract
Abstract Background Monocytes comprise subsets of classical, intermediate and non-classical monocytes with distinct anti- or pro-tumor effects in breast cancer (BC). They are modulated by estrogen, and can contribute to BC control by endocrine therapy in preclinical models. Methods To elucidate whether changes in monocyte subsets are associated with treatment and response, we investigated peripheral blood samples of 73 postmenopausal women with estrogen receptor (ER) positive BC, who received aromatase inhibitor therapy with or without the mucin-1 vaccine tecemotide in the ABCSG34 trial. Blood was retrieved at baseline, midterm and end of therapy, and was analyzed for the distribution and ER expression of monocyte subsets by flow cytometry. Results When 40 healthy, age-matched women were compared with BC patients before treatment start, ER levels of monocytes did not differ, yet patients presented with a higher frequency of classical and fewer non-classical monocytes. Endocrine therapy triggered a significant increase in ER levels in all monocyte subsets, without affecting subset distribution. Vaccination had no overall impact on subset frequency and ER expression. Yet, a shift from intermediate to classical monocytes during therapy correlated with changes in plasma cytokines and chemokines and was significantly associated with low residual cancer burden in vaccinated patients. Without tecemotide, baseline ER levels in classical monocytes were significantly higher in women with good response to endocrine therapy. Conclusions This study identified classical monocytes to be associated with ER positive BC and with patient response to neoadjuvant endocrine treatment and cancer vaccination.
- Published
- 2024
- Full Text
- View/download PDF